Join
Live feed
·
PRReleasevia Quantisnow
Kamada Ltd. logo

Kamada Announces Discontinuation of its Phase 3 Inhaled AAT Clinical Trial; Reiterates 2025 Full-Year Guidance and Projects Double-Digit Growth in Revenues and Profitability in 2026

ByQuantisnow·Wall Street's wire, on your screen.
KMDA· Kamada Ltd.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track KMDA (Kamada Ltd.) and more on Quantisnow.